Theoretical Schemas to Guide Back Pain Consortium (BACPAC) Chronic Low Back Pain Clinical Research.

Authors:
Chau A; Steib S; Whitaker E; Kohns D; Quinter A and 17 more

Journal:
Pain Med

Publication Year: 2023

DOI:
10.1093/pm/pnac196

PMCID:
PMC10403312

PMID:
36562563

Journal Information

Full Title: Pain Med

Abbreviation: Pain Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Psychophysiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the keywords and medical subject headings were selected to capture diverse but relevant systematic reviews and meta-analyses ( supplementary data 1 ).; to enable application to the final set of reviews minor modifications were made to the amstar 2 template ( supplementary data 2 ).; across the 45 studies the study authors individually presented conclusions on soe for 89 rpf-outcome associations ( supplementary data 3 )."

Code Sharing
Evidence found in paper:

"Conflicts of interest: Anthony Chiu, Sharis Steib, Evans Whitaer, David Kohns, Alexader Quinter, Anita Craig, Anthony Chiodo, SriKrishan Chandran, Ann Laidlaw, Zachary Schott, Nathan Farlow, John Yarjanian, Ashley Omwanghe, Ronald Wasserman, Anton Bowden, William Marras, Tim Carey, Wolf Mehling, Anthony Hunt declare no conflict of interest for this work. Jeffrey Lotz has royalties/licenses with Aclarion, royalties/licenses/consulting fees with Relievant MedSystems, and stock/stock options with Relievant MedSystems, Aclarion, and Bioniks, and is the Secretary of the International Society for the Study of the Lumbar Spine ISSLS (no payments). Dan Clauw performs consulting and receives consulting fees from Pfizer, Lilly, Tonix, Virias, IMC, Lundbeck, Teva, Aptinyx, and Sammumed. He also received payments for an expert testimony against opioid manufacturers in Oklahoma and Florida. Conor O'Neill has stock/stock options with and Aclarion."

Evidence found in paper:

"Funding This article was developed as part of the National Institutes of Health (NIH) Back Pain Consortium (BACPAC) Research Program that was funded as part of the NIH Helping to End Addiction Long-term Initiative (HEAL Initiative) (U19AR076737). Conflicts of interest: Anthony Chiu, Sharis Steib, Evans Whitaer, David Kohns, Alexader Quinter, Anita Craig, Anthony Chiodo, SriKrishan Chandran, Ann Laidlaw, Zachary Schott, Nathan Farlow, John Yarjanian, Ashley Omwanghe, Ronald Wasserman, Anton Bowden, William Marras, Tim Carey, Wolf Mehling, Anthony Hunt declare no conflict of interest for this work. Jeffrey Lotz has royalties/licenses with Aclarion, royalties/licenses/consulting fees with Relievant MedSystems, and stock/stock options with Relievant MedSystems, Aclarion, and Bioniks, and is the Secretary of the International Society for the Study of the Lumbar Spine ISSLS (no payments). Dan Clauw performs consulting and receives consulting fees from Pfizer, Lilly, Tonix, Virias, IMC, Lundbeck, Teva, Aptinyx, and Sammumed. He also received payments for an expert testimony against opioid manufacturers in Oklahoma and Florida. Conor O'Neill has stock/stock options with and Aclarion. Authorship has been granted only to those individuals who have contributed substantively to the work presented in this article. Study registration: Open Science Framework (Center of Open Science; https://osf.io/8ajvf)."

Evidence found in paper:

"Funding: This article was developed as part of the National Institutes of Health (NIH) Back Pain Consortium (BACPAC) Research Program that was funded as part of the NIH Helping to End Addiction Long-term Initiative (HEAL Initiative) (U19AR076737).: Conflicts of interest: Anthony Chiu, Sharis Steib, Evans Whitaer, David Kohns, Alexader Quinter, Anita Craig, Anthony Chiodo, SriKrishan Chandran, Ann Laidlaw, Zachary Schott, Nathan Farlow, John Yarjanian, Ashley Omwanghe, Ronald Wasserman, Anton Bowden, William Marras, Tim Carey, Wolf Mehling, Anthony Hunt declare no conflict of interest for this work. Jeffrey Lotz has royalties/licenses with Aclarion, royalties/licenses/consulting fees with Relievant MedSystems, and stock/stock options with Relievant MedSystems, Aclarion, and Bioniks, and is the Secretary of the International Society for the Study of the Lumbar Spine ISSLS (no payments). Dan Clauw performs consulting and receives consulting fees from Pfizer, Lilly, Tonix, Virias, IMC, Lundbeck, Teva, Aptinyx, and Sammumed. He also received payments for an expert testimony against opioid manufacturers in Oklahoma and Florida. Conor O'Neill has stock/stock options with and Aclarion.: Authorship has been granted only to those individuals who have contributed substantively to the work presented in this article.: Study registration: Open Science Framework (Center of Open Science; https://osf.io/8ajvf)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025